Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Free Cash Flow (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Free Cash Flow for 10 consecutive years, with -$25.4 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 34.73% to -$25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$115.7 million through Dec 2025, down 1.58% year-over-year, with the annual reading at -$116.6 million for FY2025, 2.41% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$25.4 million at Rhythm Pharmaceuticals, up from -$26.6 million in the prior quarter.
  • The five-year high for Free Cash Flow was -$18.8 million in Q4 2024, with the low at -$53.8 million in Q1 2022.
  • Average Free Cash Flow over 5 years is -$34.3 million, with a median of -$33.8 million recorded in 2021.
  • The sharpest move saw Free Cash Flow plummeted 60.27% in 2022, then skyrocketed 37.87% in 2023.
  • Over 5 years, Free Cash Flow stood at -$40.5 million in 2021, then rose by 16.13% to -$34.0 million in 2022, then increased by 13.58% to -$29.4 million in 2023, then skyrocketed by 35.86% to -$18.8 million in 2024, then plummeted by 34.73% to -$25.4 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$25.4 million, -$26.6 million, and -$23.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.